Insider Selling: ShockWave Medical, Inc. (NASDAQ:SWAV) CFO Sells 1,100 Shares of Stock
Insider Selling: ShockWave Medical, Inc. (NASDAQ:SWAV) CFO Sells 1,100 Shares of Stock
ShockWave Medical, Inc. (NASDAQ:SWAV – Get Rating) CFO Dan Puckett sold 1,100 shares of the firm's stock in a transaction that occurred on Tuesday, December 20th. The stock was sold at an average price of $212.93, for a total value of $234,223.00. Following the transaction, the chief financial officer now owns 39,938 shares in the company, valued at $8,503,998.34. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
冲击波医疗公司(纳斯达克代码:SWAV-GET评级)首席财务官丹·帕克特在12月20日(星期二)的一笔交易中出售了1,100股该公司的股票。这只股票的平均售价为212.93美元,总价值为234,223.00美元。交易完成后,这位首席财务官现在拥有该公司39,938股,价值8,503,998.34美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过此超链接.
Dan Puckett also recently made the following trade(s):
丹·帕克特最近还进行了以下交易:
- On Monday, November 21st, Dan Puckett sold 1,100 shares of ShockWave Medical stock. The stock was sold at an average price of $246.96, for a total value of $271,656.00.
- On Thursday, October 20th, Dan Puckett sold 1,100 shares of ShockWave Medical stock. The stock was sold at an average price of $268.35, for a total value of $295,185.00.
- 11月21日,星期一,丹·帕克特出售了1,100股Shockwave Medical的股票。这只股票的平均售价为246.96美元,总价值为271,656.00美元。
- 10月20日星期四,丹·帕克特出售了1100股冲击波医疗公司的股票。这只股票的平均售价为268.35美元,总价值为295,185.00美元。
ShockWave Medical Stock Down 2.6 %
冲击波医疗类股下跌2.6%
Shares of NASDAQ:SWAV opened at $215.20 on Friday. The stock has a fifty day simple moving average of $253.56 and a two-hundred day simple moving average of $245.49. The stock has a market capitalization of $7.78 billion, a price-to-earnings ratio of 92.36 and a beta of 0.95. ShockWave Medical, Inc. has a 12-month low of $113.36 and a 12-month high of $320.54. The company has a current ratio of 7.29, a quick ratio of 6.02 and a debt-to-equity ratio of 0.04.
上周五,纳斯达克的股价开盘报215.20美元。该股的50日简单移动均线切入位为253.56美元,200日简单移动均线切入位为245.49美元。该股市值为77.8亿美元,市盈率为92.36倍,贝塔系数为0.95。Shockwave Medical,Inc.的12个月低点为113.36美元,12个月高位为320.54美元。该公司的流动比率为7.29,速动比率为6.02,债务权益比率为0.04。
Institutional Inflows and Outflows
机构资金流入和流出
Analysts Set New Price Targets
分析师设定新的价格目标
A number of equities research analysts have recently weighed in on SWAV shares. Morgan Stanley lifted their price objective on ShockWave Medical from $255.00 to $290.00 and gave the stock an "equal weight" rating in a research report on Tuesday, October 11th. Oppenheimer lowered ShockWave Medical from a "market perform" rating to an "underperform" rating and set a $165.00 price objective on the stock. in a research report on Tuesday, September 6th. Deutsche Bank Aktiengesellschaft started coverage on ShockWave Medical in a research report on Friday, December 16th. They issued a "buy" rating and a $285.00 price objective on the stock. Wells Fargo & Company lowered ShockWave Medical from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $300.00 to $235.00 in a research report on Monday, December 12th. Finally, Bank of America lifted their price objective on ShockWave Medical from $260.00 to $310.00 in a research report on Monday, November 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $258.22.
许多股票研究分析师最近纷纷买入SWAV股票。10月11日,摩根士丹利在一份研究报告中将冲击波医疗的目标股价从255.00美元上调至290.00美元,并给予该股“同等权重”的评级。奥本海默将Shockwave Medical的评级从“市场表现”下调至“表现不佳”,并为该股设定了165.00美元的目标价。在9月6日星期二的一份研究报告中。德意志银行Aktiengesellschaft在12月16日星期五的一份研究报告中开始报道Shockwave Medical。他们对该股给予了“买入”评级和285.00美元的目标价。12月12日,富国银行在一份研究报告中将Shockwave Medical的评级从增持下调至持平,并将该股的目标价从300.00美元下调至235.00美元。最后,美国银行在11月7日星期一的一份研究报告中将Shockwave Medical的目标价从260.00美元上调至310.00美元。一名投资分析师对该股的评级为卖出,两名分析师给出了持有评级,六名分析师给出了买入评级。根据MarketBeat的数据,该公司的普遍评级为“适度买入”,平均目标价为258.22美元。
ShockWave Medical Company Profile
冲击波医疗公司简介
(Get Rating)
(获取评级)
ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.
Shockwave Medical,Inc.是一家医疗设备公司,致力于开发和商业化血管内碎石技术,用于治疗全球外周血管、冠状动脉和心脏瓣膜疾病患者的钙化斑块。该公司提供用于治疗膝关节以上外周动脉疾病(PAD)的M5导管;用于治疗冠状动脉疾病的C2导管;以及用于治疗膝盖以下PAD的S4导管。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on ShockWave Medical (SWAV)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- 免费获取StockNews.com关于Shockwave Medical(SWAV)的研究报告
- 你买下Palantir的决定可能只是个时间问题
- 卡特彼勒和迪尔准备在2023年重整旗鼓吗?
- 马伦汽车公司在i-Go登陆欧洲之际受到震动
- 2023年,太阳会照耀这3只大盘太阳能股吗?
- Lucid Motors面临的现实可能会给看涨的看法蒙上阴影
Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.
接受《冲击波医学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对ShockWave Medical和相关公司的最新新闻和分析师评级的每日简要摘要。